Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
The major symptom of many short and long-term illnesses is pain, both chronic and acute. Disorders such as Multiple Sclerosis, Diabetic Neuropathy and others, whether derived from the primary or central nervous system, leave patients with unrelenting pain not easily controlled by common pain medications. Although few randomized clinical trials over sufficiently extended periods of time measuring the effects of cannabidiol oil intake on pain management exist, preliminary studies suggest the use of CBD’s in chronic pain management to be useful allowing an increase in quality of life and the ability to rest without pain. There is some research out there that suggests this might be a good solution for those that are sensitive to other medications as well. We have attached some Medical publications, News Articles and some videos that touch on this subject.
Receptra offers their products in two separate lines. One is the Active Lifestyle range, which provides lower concentrations for daily use, and another is Health and Wellness, which is for far more intense use. It is incredibly difficult for me to manage my back pain with a low concentration of CBD usually, so, I went with the 3000 mg concentration available in their Health and Wellness line.
While CBD still faces legal hurdles to go mainstream, beverage giants, food companies and others have begun to take serious interest in the roughly $2 billion U.S. market. Tilray Inc. TLRY, +0.68% announced a partnership with Anheuser-Busch InBev SA BUD, -1.34% this week to research marijuana-based beverages, and Constellation Brands Inc. STZ, -0.03% has invested heavily in pot producer Canopy Growth Corp. Other large companies, like Molson Coors Brewing Co. TAP, -0.17% , have invested in research, and Coca-Cola Co. KO, -0.26% and others have at least considered making a play for the space.
Then come Chapters 5 through 13, the heart of the report, which concern marijuana’s potential risks. The haze of uncertainty continues. Does the use of cannabis increase the likelihood of fatal car accidents? Yes. By how much? Unclear. Does it affect motivation and cognition? Hard to say, but probably. Does it affect employment prospects? Probably. Will it impair academic achievement? Limited evidence. This goes on for pages.
In 2017, the cultivated area for hemp in the Prairie provinces include Saskatchewan with more than 56,000 acres (23,000 ha), Alberta with 45,000 acres (18,000 ha), and Manitoba with 30,000 acres (12,000 ha). Canadian hemp is cultivated mostly for its food value as hulled hemp seeds, hemp oils and hemp protein powders, with only a small fraction devoted to production of hemp fiber used for construction and insulation.
To be clear, there is no one specific test, scan, or anything else of the sort that you can do to determine whether or not you need CBD oil for pain. Also, since cannabis is not yet recognized by the FDA, you unfortunately can’t really go to your doctor either and have them recommend it; until marijuana is FDA-approved, it cannot be prescribed by physicians.